Form 4: Celldex Therapeutics Director James Marino Granted 16,500 Stock Options

Celldex Therapeutics, Inc. (CLDX) director James J. Marino was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring in 2035.

Summary

• James J. Marino, a Director of Celldex Therapeutics, Inc. (CLDX), was granted 16,500 non-qualified stock options.
• The options have an exercise price of $19.53 per share.
• The transaction date for the grant was June 5, 2025.
• These options become exercisable on June 5, 2026, and will expire on June 5, 2035.
• The grant was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
• Following this transaction, Mr. Marino beneficially owns 16,500 derivative securities (options).

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director's interests with shareholder value through equity compensation, a standard practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options are granted under an existing, approved equity incentive plan (2021 Omnibus Equity Incentive Plan), indicating a structured approach to executive compensation.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although this is a standard aspect of equity compensation plans.

Future Outlook

NA

Industry Context

This is a routine insider compensation disclosure common across all industries, particularly in biotechnology where equity incentives are a significant part of compensation packages to attract and retain talent. It reflects standard corporate governance practices for aligning director interests with company performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to James J. Marino, a director of Celldex Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from increased alignment of director's interests with company performance.
• Director (James J. Marino): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The director may choose to exercise the options after they become exercisable on June 5, 2026, assuming the stock price is above the exercise price of $19.53.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, insider transaction, stock option grant, director compensation, equity incentive, James J. Marino, beneficial ownership